Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Long-Term Deferred Tax: 2022

Historic Long-Term Deferred Tax for Spyre Therapeutics (SYRE) over the last 1 years, with Dec 2022 value amounting to $566,000.

  • Spyre Therapeutics' Long-Term Deferred Tax was N/A to $566,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $566,000, marking a year-over-year change of. This contributed to the annual value of $566,000 for FY2022, which is N/A change from last year.
  • Spyre Therapeutics' Long-Term Deferred Tax amounted to $566,000 in FY2022.
  • Over the past 5 years, Spyre Therapeutics' Long-Term Deferred Tax peaked at $566,000 during FY2022, and registered a low of $566,000 during FY2022.
  • In the last 1 years, Spyre Therapeutics' Long-Term Deferred Tax had a median value of $566,000 in 2022 and averaged $566,000.